Evidence map›Paper›PMID 39694479›Full record

ReviewInternal medicine (Tokyo, Japan)2026

Migraine Management in Japan: Current Approaches and Science Narrative Including an Evidence-based Review.

Takao Takeshima, Shoji Kikui, Daisuke Danno

Abstract readReview
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Takao TakeshimaDepartment of Neurology, Headache Center, Tominaga Hospital, Japan.
Shoji KikuiDepartment of Neurology, Headache Center, Tominaga Hospital, Japan.
Daisuke DannoDepartment of Neurology, Headache Center, Tominaga Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a prevalent and highly disabling neurological disorder. Recent progress in neuroscientific research has contributed to the development of new therapies for migraine, including triptans, ditans, calcitonin gene-related peptide (CGRP) antagonists, and CGRP-related monoclonal antibodies. Noninvasive neuromodulation devices have also been developed. We herein review the recent advances in research and the current standard of management for migraine patients.

Indexed as

Migraine DisordersCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsDisease ManagementEvidence-Based MedicineHumansJapanTryptaminesCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsTryptaminescalcitonin gene-related peptide (CGRP)neuromodulationpharmacotherapy

Identifiers

PMID39694479
PMCPMC12854955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.